Advancements in antibody engineering technologies have greatly enhanced the generation of recombinant antibodies in various formats as therapeutic agents. There are already more than 100 antibody-based drugs approved by the FDA, and numerous antibodies are currently in their late-stage clinical studies. Compared to monoclonal antibodies produced using traditional hybridoma techniques, recombinant antibodies offer advantages, such […]

- Home
- News
- DDW Exclusive Content
- Opinion
- Business
- Regulatory
- Intelligence
Categories
Latest Industry Intelligence
- Cancer Research
- Webinars
- Podcasts
- Archive
- Videos